Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma

We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Barajas, Ramon F., Pampaloni, Miguel H., Clarke, Jennifer L., Seo, Youngho, Savic, Dragana, Hawkins, Randall A., Behr, Spencer C., Chang, Susan M., Berger, Mitchel, Dillon, William P., Cha, Soonmee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/
https://www.ncbi.nlm.nih.gov/pubmed/25793136
http://dx.doi.org/10.1155/2015/731361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/
https://www.ncbi.nlm.nih.gov/pubmed/25793136
http://dx.doi.org/10.1155/2015/731361

Ejemplares similares